240 related articles for article (PubMed ID: 18513385)
1. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.
Noetzel E; Veeck J; Niederacher D; Galm O; Horn F; Hartmann A; Knüchel R; Dahl E
BMC Cancer; 2008 May; 8():154. PubMed ID: 18513385
[TBL] [Abstract][Full Text] [Related]
2. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.
Carey JP; Asirvatham AJ; Galm O; Ghogomu TA; Chaudhary J
BMC Cancer; 2009 Jun; 9():173. PubMed ID: 19500415
[TBL] [Abstract][Full Text] [Related]
4. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
Nasif D; Campoy E; Laurito S; Branham R; Urrutia G; Roqué M; Branham MT
Clin Epigenetics; 2018 Aug; 10(1):111. PubMed ID: 30139383
[TBL] [Abstract][Full Text] [Related]
6. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
Umetani N; Mori T; Koyanagi K; Shinozaki M; Kim J; Giuliano AE; Hoon DS
Oncogene; 2005 Jul; 24(29):4721-7. PubMed ID: 15897910
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer.
Sharma P; Chinaranagari S; Patel D; Carey J; Chaudhary J
Cancer Med; 2012 Oct; 1(2):176-86. PubMed ID: 23342267
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.
Gao XZ; Zhao WG; Wang GN; Cui MY; Zhang YR; Li WC
Mol Med Rep; 2016 Feb; 13(2):1269-74. PubMed ID: 26648013
[TBL] [Abstract][Full Text] [Related]
10. CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.
Nasif D; Real S; Roqué M; Branham MT
Breast Cancer; 2022 May; 29(3):562-573. PubMed ID: 35094293
[TBL] [Abstract][Full Text] [Related]
11. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
12. Hormonal regulation and differential actions of the helix-loop-helix transcriptional inhibitors of differentiation (Id1, Id2, Id3, and Id4) in Sertoli cells.
Chaudhary J; Johnson J; Kim G; Skinner MK
Endocrinology; 2001 May; 142(5):1727-36. PubMed ID: 11316735
[TBL] [Abstract][Full Text] [Related]
13. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma.
Seniski GG; Camargo AA; Ierardi DF; Ramos EA; Grochoski M; Ribeiro ES; Cavalli IJ; Pedrosa FO; de Souza EM; Zanata SM; Costa FF; Klassen G
BMC Cancer; 2009 Mar; 9():80. PubMed ID: 19267929
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
15. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
16. Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients.
Cen J; Shen J; Wang X; Kang H; Wang L; Sun L; Li Y; Yu L
Oncol Rep; 2013 Jul; 30(1):455-61. PubMed ID: 23670122
[TBL] [Abstract][Full Text] [Related]
17. Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.
Donzelli S; Milano E; Pruszko M; Sacconi A; Masciarelli S; Iosue I; Melucci E; Gallo E; Terrenato I; Mottolese M; Zylicz M; Zylicz A; Fazi F; Blandino G; Fontemaggi G
Breast Cancer Res; 2018 Jun; 20(1):59. PubMed ID: 29921315
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
[TBL] [Abstract][Full Text] [Related]
19. Prognostic values of the inhibitor of DNA‑binding family members in breast cancer.
Zhou XL; Zeng D; Ye YH; Sun SM; Lu XF; Liang WQ; Chen CF; Lin HY
Oncol Rep; 2018 Oct; 40(4):1897-1906. PubMed ID: 30066902
[TBL] [Abstract][Full Text] [Related]
20. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.
Gómez Del Pulgar T; Valdés-Mora F; Bandrés E; Pérez-Palacios R; Espina C; Cejas P; García-Cabezas MA; Nistal M; Casado E; González-Barón M; García-Foncillas J; Lacal JC
Int J Oncol; 2008 Jul; 33(1):185-93. PubMed ID: 18575765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
